Search clinical trials for: Switching trial from ropinirole to rotigotine,

Total 477284 results

UCB Pharma

Completed

Named Patient Program With Rotigotine Transdermal System

Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine

United States
UCB Pharma

Completed

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease. (SP512OL)

Early-Stage Parkinson's Disease

United States, Canada
I.R.C.C.S. Fondazione Santa Lucia
Alzheimer's Drug Discovery Foundation

Active, not recruiting

Dopaminergic Therapy for Frontotemporal Dementia Patients

Mental Disorders | Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Neurologic Manifestations | Neurobehavioral Manifestations | Neurocognitive Disorders | Neurodegenerative Diseases | TDP-43 Proteinopathies | Proteostasis Deficiencies | Dementia | Language Disorders | Communication... and other conditions

Italy
UCB Pharma

Completed

Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine

Parkinson's Disease
UCB BIOSCIENCES GmbH
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease

Advanced Idiopathic Parkinson's Disease

Korea, Republic of, United States, Malaysia, Singapore, Taiwan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome (RLS)

Idiopathic Restless Legs Syndrome
UCB Pharma
Otsuka Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Rotigotine Transdermal Patch With Two Different Formulations in Healthy Japanese Subjects

Healthy Volunteers

Germany
UCB Pharma

Completed

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease

Early Stage Parkinson's Disease

Poland, United Kingdom, Germany, Spain, Switzerland, Belgium, South Africa, New Zealand, Czech Republic, Austria, Hungary, Australia, Italy, Israel, Sweden, Norway, Croatia, Netherlands, Finland, France
UCB Pharma

Completed

An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease

Idiopathic Parkinson's Disease

United States, Germany, Spain, Austria, Israel, Italy, South Africa, United Kingdom
UCB Pharma

Completed

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease (SP715)

Parkinson's Disease

United States, Canada
UCB BIOSCIENCES GmbH
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease

Advanced Parkinson's Disease

Australia, Korea, Republic of, Malaysia, Singapore, Taiwan
SocraTec R&D GmbH
Luye Pharma Group Ltd.; SocraMetrics GmbH

Completed

Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients With Parkinson's Disease

Parkinson Disease

Germany
UCB Pharma

Completed

Study to Compare Adhesiveness of Two Different Rotigotine Patch Formulations

Parkinson's Disease

Germany, Austria, United Kingdom
UCB Biopharma SRL

Terminated

A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome

Restless Legs Syndrome

United States
UCB Pharma

Completed

Study in Healthy Volunteers to Prove That Two Rotigotine Patches From Different Manufacturing Sites Deliver Equivalent Drug Amount to the Body

Healthy Volunteers

Germany
UCB Pharma

Completed

Long-term Open-label Trial in Idiopathic Restless Legs Syndrome (RLS)

Restless Legs Syndrome

Germany, Spain, Austria
UCB Pharma

Completed

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine Transdermal Patch in Healthy Chinese Subjects

Healthy

China
UCB Pharma

Completed

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease

Advanced Stage Parkinson's Disease

France, Italy, Poland, United Kingdom, Spain, Germany, South Africa, New Zealand, Czech Republic, Hungary, Australia, Austria, Israel, Sweden, Norway, Croatia, Finland
John Winkelman, MD, PhD
UCB Pharma

Completed

Switching From Oral Dopamine Agonists to Rotigotine (SWITCH)

Restless Legs Syndrome | Ekbom Syndrome | Willis-Ekbom Disease

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients

Parkinson's Disease

Japan
UCB Pharma GmbH

Completed

Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease (NEUPAD)

Idiopathic Parkinson's Disease

Germany, Austria
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients

Parkinson's Disease

Japan
I.R.C.C.S. Fondazione Santa Lucia

Completed

Effects of Dopaminergic Therapy in Patients With Alzheimer's Disease (DOPAD)

Alzheimer Disease

Italy
UCB Pharma

Completed

Transdermal Rotigotine User Surveillance Study (TRUST)

Idiopathic Parkinson Disease

Czechia, Denmark, Germany, Greece, Italy, Mexico, Romania, Slovakia, Spain, Switzerland
UCB Pharma SA

Completed

Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch Comparing 2 Different Formulations

Healthy

China
UCB Pharma

Completed

Rotigotine Restless Legs Syndrome Dose Finding Trial

Idiopathic Restless Leg Syndrome

Germany
UCB BIOSCIENCES GmbH

Completed

Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Repeated Dose Transdermal Rotigotine in Japanese and Caucasian Subjects

Healthy

Germany
UCB Pharma

Completed

Phase 3 Open-label Extension Trial With Rotigotine in Idiopathic Restless Legs Syndrome Subjects

Idiopathic Restless Legs Syndrome

Germany
UCB BIOSCIENCES GmbH
Pharmaceutical Health Sciences; Bracket Global

Completed

A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's Disease

Parkinson's Disease

Germany
UCB Biopharma SRL

Terminated

A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause

Restless Legs Syndrome

United States
UCB Pharma

Completed

A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease

Parkinson's Disease

United States
UCB Pharma

Completed

Study in Healthy Volunteers to Prove That 2 Rotigotine Patches From Different Manufacturing Processes Deliver Equivalent Drug Amount to the Body.

Healthy

Germany
UCB Pharma

Completed

The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults. (SP888)

Fibromyalgia Syndrome

United States
Peking University Third Hospital

Completed

Efficacy and Safety of Rotigotine in the Treatment of Patients With Early Stage of Primary Parkinson's Disease

Parkinson's Disease

China
UCB Pharma

Completed

Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in Healthy Korean Subjects

Parkinson's Disease

Korea, Republic of
Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients

Parkinson's Disease

Japan
Luye Pharma Group Ltd.

Completed

Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease

Parkinson Disease

United States
Serina Therapeutics

Active, not recruiting

A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214

Parkinson's Disease

United States
UCB Pharma

Completed

Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms

Parkinson's Disease
Sandoz

Terminated

An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.

Parkinson Disease

Germany
Inflamax Research Incorporated

Completed

Irritation and Sensitization Potential of Repeat Applications of Rotigotine Patch

Bioequivalence - Irritation and Sensitization Potential of Transdermal Patch

United States, Canada
UCB Pharma

Terminated

Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease

Parkinson's Disease

Spain, South Africa, New Zealand, Hungary, United States, Germany, Italy, Australia, Finland, United Kingdom, Poland
UCB BIOSCIENCES GmbH
Schwarz BioSciences GmbH; Alfred-Nobel-Str. 10; 40789 Monheim am Rhein

Completed

Study to Evaluate the Pharmacokinetics (PK), Safety, Tolerability of Single-Dose Transdermal Rotigotine in Japanese and Caucasian Healthy Male / Female Subjects

Healthy

Germany
Otsuka Pharmaceutical Co., Ltd.

Completed

A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) Patients

Idiopathic Restless Legs Syndrome

Japan
UCB Pharma

Completed

Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of RLS Symptoms

Restless Legs Syndrome

Germany
Otsuka Pharmaceutical Co., Ltd.

Completed

A Trial to Explore Symptomatic Therapy for Application Site Reaction to SPM962 in Healthy Subject

Healthy

Korea, Republic of
Luye Pharma Group Ltd.

Completed

Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease

Parkinson's Disease

United States
UCB Pharma

Completed

Study in Healthy Volunteers to Prove That Two Different Formulations of Rotigotine Patches Deliver Equivalent Drug Amount to the Body

Healthy Volunteers

Germany
Virginia Commonwealth University
National Institute on Drug Abuse (NIDA)

Recruiting

Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder

Substance-Related Disorders

United States
Luye Pharma Group Ltd.
Beijing Bozhiyin T&S Co., Ltd.

Completed

A Study of LY03003 in Patients With Early-stage Parkinson's Disease

Parkinson Disease

3

Subscribe